Tasidotin hydrochloride (BioDeep_00000812974)
代谢物信息卡片
化学式: C32H59ClN6O5 (642.4235234)
中文名称: TASIDOTIN 盐酸盐
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC(C)C(C(=O)N(C)C(C(C)C)C(=O)N1CCCC1C(=O)N2CCCC2C(=O)NC(C)(C)C)NC(=O)C(C(C)C)N(C)C.Cl
InChI: /m0./s1
描述信息
C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C273 - Antimitotic Agent
同义名列表
1 个代谢物同义名
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Lindsay B Kilburn, Peter L Bonate, Susan M Blaney, Leticia McGuffey, Jed G Nuchtern, Robert Dauser, Patrick Thompson, Brian W Gibson, Stacey L Berg. Plasma and cerebrospinal fluid pharmacokinetics of tasidotin (ILX-651) and its metabolites in non-human primates.
Cancer chemotherapy and pharmacology.
2009 Jul; 64(2):335-40. doi:
10.1007/s00280-008-0875-7. [PMID: 19043710] - Peter L Bonate, David Beyerlein, Jennifer Crawford, Stephanie Roth, Roy Krumbholz, Steve Schmid. Pharmacokinetics in mice implanted with xenografted tumors after intravenous administration of tasidotin (ILX651) or its carboxylate metabolite.
The AAPS journal.
2007 Dec; 9(3):E378-87. doi:
10.1208/aapsj0903045. [PMID: 18170985] - Alain C Mita, Lisa A Hammond, Peter L Bonate, Geoffrey Weiss, Heather McCreery, Samira Syed, Mitchell Garrison, Quincy S C Chu, Johann S DeBono, Christopher B Jones, Steve Weitman, Eric K Rowinsky. Phase I and pharmacokinetic study of tasidotin hydrochloride (ILX651), a third-generation dolastatin-15 analogue, administered weekly for 3 weeks every 28 days in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2006 Sep; 12(17):5207-15. doi:
10.1158/1078-0432.ccr-06-0179. [PMID: 16951240] - Scot Ebbinghaus, Eric Rubin, Evan Hersh, Lee D Cranmer, Peter L Bonate, Robert J Fram, Antti Jekunen, Steve Weitman, Lisa A Hammond. A phase I study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously daily for 5 consecutive days every 3 weeks in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2005 Nov; 11(21):7807-16. doi:
10.1158/1078-0432.ccr-05-0909. [PMID: 16278403] - Casey Cunningham, Leonard J Appleman, Miora Kirvan-Visovatti, David P Ryan, Eileen Regan, Svetislava Vukelja, Peter L Bonate, Francis Ruvuna, Robert J Fram, Antti Jekunen, Steve Weitman, Lisa A Hammond, Joseph P Eder. Phase I and pharmacokinetic study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously on days 1, 3, and 5 every 3 weeks in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2005 Nov; 11(21):7825-33. doi:
10.1158/1078-0432.ccr-05-0058. [PMID: 16278405]